UBS Group’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

UBS Group’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-7	Closed	-$24K	–	9518
2014 Q4	$24K	Buy	+7	New	+$21.5K	﹤0.01%	7402

Other funds holding NBSE

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

UBS Group's NBSE Position: Q2 2024 in Review

UBS Group sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2024, closing a stake of 4,056 shares — an estimated $1.82K sold.

UBS Group first reported a position in NBSE in Q4 2014 and held it in 34 quarters. The position peaked at $290K in Q4 2014. 3 funds tracked by Wall St. Rank hold NBSE as of Q2 2024.

UBS Group reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
UBS Group sold 4,056 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $1.82K.
UBS Group first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q4 2014 and held it in 34 quarters.
UBS Group's NeuBase Therapeutics, Inc. Common Stock position peaked at $290K in Q4 2014.
3 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2024.

Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.